The National Institute of Alcohol Abuse and Alcoholism (NIAAA) is seeking letters of interest (LOIs) for promising medications (both novel compounds and repurposed medications) to evaluate their efficacy and safety in Phase 1 and 2 clinical trials for the treatment of alcohol use disorder (AUD). Clinical trials will be supported by a NIAAA contract and conducted by NIAAA’s Alcohol Pharmacotherapy Evaluation Program (APEP). This program includes studies conducted by the NIAAA Clinical Investigations Group (NCIG), Human Laboratory Program (HLAB), and Alcohol Interaction program (ALC InX). Studies supported under this mechanism are designed by the APEP team and utilize established paradigms and protocols developed in collaboration with the medication’s stakeholders. APEP trials are generally completed within 1.5 years and are conducted under Good Clinical Practice (GCP).
The LOI must be emailed to Dr. Daniel Falk (falkde@mail.nih.gov) no later than September 15th, 2023.
NOT-AA-23-016